Mislabeling Leads to 17 Cases of Infant “Werewolf Syndrome”

Children in Spain have developed hypertrichosis after a reflux drug was contaminated with alopecia treatment.

Infant Werewolf Syndrome / Image: Shutterstock
Infant Werewolf Syndrome / Image: Shutterstock

The headline may sound like a festive Halloween ruse, but according to a recent European Pharmaceutical Review article, kids in Spain are developing ‘werewolf syndrome’ after a packaging error. There have been at least 17 cases reported in which infants have grown abnormal body hair after taking omeprazole for gastroesophageal reflux disease. The drug administered was contained minoxidil, a medication used to treat alopecia.

Farma-Química Sur, the company that produces the drug, purchased a batch of minoxidil from a generic drug supplier in India. A labeling error at the plant caused the two to be mixed, resulting in the hairy babies. The company told parents that the excess hair should fall out and the babies should be back to normal in a few weeks.

Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
Sustainable Healthcare Packaging Solutions That Work
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO